Sandoz Invests In Its Unique Antibiotics Offering

CEO Richard Saynor Outlines The Attraction Of Recently-Closed Deal With GSK

 
• By Dave Wallace

In the wake of a major deal to acquire GlaxoSmithKline’s cephalosporins business, Sandoz CEO Richard Saynor has set out why the company’s unique position means that antibiotics are an important area for investments, in an exclusive interview with Generics Bulletin.

Sandoz Logo Phone Screen Red Yellow Capsules
Sandoz has further committed to antibiotics with the GSK deal • Source: Alamy

More from Strategy

More from Business